Clinical trials: Meropenem
Lower Respiratory Tract Infection
Approach for Optimizing Meropenem Therapy in Intubated and Mechanically-Ventilated, Adult Patients With Severe Gram-Negative Lower Respiratory Tract Infection
Antibacterial drugs are facing increasing limitations in terms of effectiveness due to emergence resistance. Improved antibacterial drug monitoring approaches are particularly needed in nosocomial infections occurring in ICU…
- Trial name
- MON4STRAT (NCT03915236)
- Testing
- MON4STRAT Strategy, Control group
- Where
- 3 sites in Belgium, France and 1 more
- Volunteers
- 7 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Urinary Tract Infections
Clinical Trial to Study the Safety and Effectiveness of MK0826 and Other Antibiotic Therapy in Patients With Complicated Urinary Tract Infection (0826-054)
The purpose of this study is to demonstrate that MK0826 is comparable to Meropenem in the treatment of complicated Urinary Tract Infections (UTIs) in adults.
- Trial name
- NCT00771316
- Testing
- MK0826 (ertapenem), Comparator: meropenem
- Volunteers
- 6 people
- Sponsor
- Merck Sharp & Dohme LLC
Meningitis
Pharmacokinetics and Safety of Meropenem in Infants Below 90 Days of Age With Probable and Confirmed Meningitis
This phase I-II multicenter international trial is designed to study the pharmacokinetics of meropenem and to characterize the safety profile of meropenem in the treatment of infants ≤ 90 days of postnatal age with probable or…
- Trial name
- NeoMero-2 (NCT01554124)
- Testing
- Meropenem
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- PENTA Foundation
Complicated Intra-abdominal Infections
Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections
The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated intra-abdominal infections as compared to a comparator group.
- Trial name
- NCT00752219
- Testing
- ceftazidime/NXL104 + metronidazole, meropenem
- Where
- 45 sites in United States, Bulgaria and 6 more
- Volunteers
- 204 people
- Sponsor
- Pfizer
Bloodstream Infections
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response
Infections of the blood are extremely serious and require intravenous antibiotic treatment. When the infection results from antibiotic resistant bacteria, the choice of antibiotic is an extremely important decision.
- Trial name
- MERINO II (NCT02437045)
- Testing
- Meropenem, Piperacillin-tazobactam combination product
- Where
- 6 sites in Australia, Singapore
- Volunteers
- 100 people
- Sponsor
- The University of Queensland
Other Infectious Diseases
Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
The goal of this clinical research study is to learn if the study drug ceftolozane-tazobactam is more effective in controlling febrile neutropenia (fever and low white blood cell counts) than using approved antibiotics in…
- Trial name
- NCT03485950
- Testing
- Cefepime, Ceftolozane, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Ventilator-Associated Pneumonia
The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia
The study was a randomized three-way crossover study. Each subject received meropenem in three regimens at room temperature consecutively: (i) bolus injection of 1 g of meropenem over 10 min every 8 h for 24 h, (ii) 3-h infusion…
- Trial name
- NCT02615041
- Testing
- Meropenem
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Sutep Jaruratanasirikul
Initial Phase of Severe Sepsis and Septic Shock
Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units
This is a prospective, noncomparative study to assess the pharmacodynamics of meropenem during early phase of severe sepsis and septic shock in critically ill patients in an intensive care unit.
- Trial name
- NCT02213796
- Testing
- Meropenem
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Sutep Jaruratanasirikul
Cystic Fibrosis, Pneumonia
Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children
This study will determine the concentrations of the antibiotic meropenem when administered as a 3 hour prolonged infusion in children with cystic fibrosis who are hospitalized with an acute pulmonary exacerbation.
- Conditions
- Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
- Trial name
- NCT01429259
- Testing
- meropenem
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Joseph Kuti
Abscess, Intra-Abdominal, Abdominal Abscess
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
- Conditions
- Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain
- Trial name
- NCT01110382
- Testing
- Doripenem, Meropenem, Amoxicillin/clavulanate potassium
- Where
- 19 sites in United States, Argentina and 6 more
- Volunteers
- 41 people
- Sponsor
- Janssen Research & Development, LLC
Infection, Renal Failure
Pharmacokinetics of Meropenem During High-dose CRRT
Assessment of meropenem plasma concentration in critically ill patients who require CRRT (continuous renal replacement therapy). A standard dose of meropenem is administered, i.e. 1 gram every 8 hours.
- Trial name
- NCT03507751
- Testing
- Meropenem, CRRT
- Where
- Poland
- Volunteers
- 19 people
- Sponsor
- Medical University of Lublin
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Enterobacteriaceae Infections
Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
Among enterobacteria, ESBL production is the leading cause of multidrug resistance. The first cases of ESBL-producing Enterobacteriaceae (EBLSE) infections were described in the 1980s and subsequently spread worldwide.
- Trial name
- MERIMI (NCT05516433)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Acute-On-Chronic Liver Failure
Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
Acute on chronic liver failure patients are at high risk for nosocomial infections due to liver dysfunction, which impairs immune responses and increases vulnerability to infections.
- Trial name
- NCT06818565
- Testing
- Meropenem Injection, Ceftazidime-avibactam, Teicoplanin
- Where
- India
- Volunteers
- 150 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Lower Respiratory Tract Infection
Meropenem Dosage Strategy Based on PPK Model
To evaluate the clinical and economical benefits of a meropenem dosage strategy based on a population pharmacokinetic(PPK)-pharmacodynamic(PD) model in lower respiratory tract infection patients.
- Trial name
- NCT01944319
- Testing
- Routine meropenem therapy, Meropenem therapy based on a PPK and PD model
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Qingtao Zhou
Sepsis, Septic Shock
Monitoring of Piperacillin-Tazobactam and Meropenem Plasmatic Levels in Critical Patients
The aim of this study is to establish the Piperacillin-Tazobactam and Meropenem Plasmatic Levels to know if it´s necessary to make some adjustment in the recommended dose regimen.
- Trial name
- NCT04257838
- Testing
- Piperacillin/tazobactam or Meropenem
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Spontaneous Bacterial Peritonitis
Meropenem vs Cefotaxime as Empirical Treatment of SBP
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.
- Trial name
- NCT05427747
- Testing
- cefotaxime
- Volunteers
- 286 people
- Sponsor
- Assiut University
Infections
Validation of Betalactam ML Prediction Models - TDMAide
The goal of this study is to learn about the real wold behavior of developed machine learning models that predict the plasma concentration of piperacillin-tazobactam and meropenem in critically ill patients admitted to the…
- Trial name
- TDMAide (NCT06026852)
- Testing
- Prediction of plasma concentration of piperacillin-tazobactam or meropenem, Determination of plasma concentration of piperacillin-tazobactam or meropenem, Daily short questionnaire
- Where
- Belgium
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD)
Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis
This study aims to investigate the pharmacokinetics (PK) and pharmacodynamic (PD) profiles of four commonly used antibiotics - meropenem, ampicillin, aztreonam, and ciprofloxacin - administered via intravenous (i.v.) and…
- Conditions
- Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD), Pharmacokinetics, Intravenous Administration
- Trial name
- NCT07113587
- Testing
- Application of intraperitoneal and intravenous meropenem in in automated peritoneal dialysis patients without peritonitis, Application of intraperitoneal and intravenous ampicillin in automated peritoneal dialysis patients without peritonitis, Application of intraperitoneal and intravenous aztreonam in automated peritoneal dialysis patients without peritonitis
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Karl Landsteiner Insitute for Nephrology and Haemato-Oncology
Complicated Urinary Tract Infection, Pyelonephritis
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.
- Trial name
- NCT03230838
- Testing
- Ceftolozane/Tazobactam, Meropenem
- Where
- 52 sites in United States, Greece and 8 more
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC